|
 |
Reglan
Nonmedication treatments that help me the most are massage, exercise, etc.
The blood tests the doctor orders depends on a number of factors. For example, if you haven't had the hepatitis B vaccination series, then you will need more tests than if you have had the series. If you decide to have HIV postexposure chemoprophylaxis, then you will need a number of tests you don't need if you decide against the medicines. One concern of most people who have a blood exposure is the status of the source patient. You may wonder if the source has the HIV, HBV, or HCV. The source can be tested. But to request the testing, you have to agree to be tested also. In other words, the source can't be tested if you aren't tested also. What if the source declines testing? If the laboratory has some of the source's blood in the lab, left over from other testing, then that blood can be used, even if the source doesn't want to be tested. If no blood is available and the source pateint refuses to be tested, a court order can be obtained to acquire a sample. From an abnormality in the remodeling process of bone in which bone resorption exceeds bone formation leading to a net loss of bone. Various hormonal and genetic factors play an important role in etiopathogenesis of osteoporosis. Depending upon these hormonal and genetic factors involutional osteoporosis is classified as type I and type II. Type I osteoporosis : It is caused by loss of gonadal hormonal function. It is seen in postmenopausal women and men after castration. The loss of gonadal hormones result in increased recruitment and responsiveness of osteoclast precursors, predominantly in trabecular bone. patients may present with fractures of distal forearm and vertebral bodies where trabecular bone is predominant. Type II osteoporosis : It is associated with aging seen after the age of 60 in both men and women. Unlike type I osteoporosis there is no primary increase in osteoclastic activity. There occurs progressive decline in supply of osteoblasts with resultant net loss of bone in both trabecular and cortical sites. This group is associated with fractures of the extra capsular hip, proximal humerus and pelvis. Index 2.6 Differences between type I and type II osteoporosis : Type I Type II Epidermiology Age 55-75 More than 70 Sex ratio F: M 6: Basic pathology Increased osteoclast activity Decreased osteoblast activity Increased resorption Decreased formation Rapid rate of bone loss Slow rate of bone loss Affected bones Mainly trabecular bone Cortical and trabecular Fracture sites Vertebral crush ; Wedge fractures vertebrae ? Intracapsular hip Proximal humerus Distal forearm Extra capsular hip Other features Tooth loss Dorsal kyphosis Laboratory changes Increased urinary excretion of Normal calcium Increased PTH function Decreased PTH function The risk factors for osteoporosis and secondary osteoporosis are discussed in chapter IV 2.7 SALIENT FEATURES OF OSTEOPOROSIS Osteoporosis is not an inevitable part of menopause or of aging. Men and younger women can also fall victim to osteoporosis. With increasing age of the population in the world, the problem of osteoporosis is assuming alarming proportions. Drugs affecting the nervous system a ; drugs affecting sympathetic nervous system i ; adrenergic sympathomimetic ; 1 ; catecholamine a ; epinephrine adrenalin ; , norepinephrine levophed ; , dopamine intropin ; , dobutamine dobutrex ; , isoproterenol isuprel ; 2 ; non-catecholamine a ; ephedrine, pseudoephedrine sudafed ; , phenylephrine hcl neo- synephrine ; , albuterol proventil ; b ; anti-adrenergic drugs i ; alpha-adrenergic blockers 1 ; phentolamine mesylate regitine ; , ergotamine tartrate ergostat ; , ergotamine tartrate with caffeine cafergot ; , doxazosin cardura ; , prazosin minipress ; , terazosin hytrin ; , ii ; beta-adrenergic blockers 1 ; propranolol inderal ; prototype ; , metoprolol tartrate lopressor ; , atenolol tenormin ; , sotalol betapace ; , timolol maleate timoptic ; c ; drugs affecting the parasympathetic nervous system i ; cholinergic 1 ; direct-acting acetylcholine prototype ; , bethanechol urecholine ; , pilocarpine pilocar ; , carbachol intraocular miostat ; , metaclopramide reglan ; 2 ; indirect-acting neostigmine prostigmin ; , edrophonium chloride tensilon ; , pyridostigmine bromide mestinon ; ii ; anticholinergics 1 ; atropine sulfate prototype ; , belladonna tincture, hematropine spectro-homatropine ; mydriasis & cyclopegia, trihexyphenidyl artane ; , oxybutynin ditropan ; , scopolamine hydrobromide hyoscine ; d ; drugs affecting the neuromuscular system i ; skeletal muscle relaxants 1 ; central carisoprodol soma ; , cyclobenzaprine flexeril ; , baclofen lioresal ; , diazepam valium ; , metaxalone skelaxin ; , methocarbamol robaxin ; , orphenadrine norflex ; , chlorzoxazone parafon forte ; , tizanidine zanaflex ; 2 ; direct-acting dantrolene dantrium ; ii ; nondepolarizing neuromuscular blocking agents - pancuronium bromide pavulon ; , vecuronium bromide norcuron ; , tubocurarine chloride tubarine ; iii ; depolarizing agents succinylcholine anectine ; e ; drugs that stimulate the cns i ; analeptics caffeine, doxapram dopram ; , theophylline ii ; psychomotor stimulants methylphenidate ritalin ; , pemoline cylert ; , amphetamine sulfate, methamphetamine hydrochloride desoxyn ; , dextroamphetamine sulfate dexedrine ; iii ; non-amphetamine anorexiants - phentermine fastin ; , phenmetrazine preludin ; , diethylproprion tenuate ; , sibutramine hydrochloride monohydrate meridia ; , orlistat ; xenical ; f ; drugs that depress the cns i ; sedatives and hypnotics 1 ; barbiturates thiopental sodium pentothal ; , phenobarbital sodium nembutal ; , secobarbital sodium seconal ; , amobarbital amytal ; 2 ; non-barbiturates - buspirone buspar ; , chloral hydrate, zolpidem tartrate ambien ; , paraldehyde, hydroxyzine vistaril ; , diphenhydramine benadryl ; , hydroxyzine atarax ; 3 ; benzodiazepines tempazepam restoril ; , diazepam valium ; , flurazepam dalmane ; , triazolam halcion benzodiazepine antidote flumazenil romazicon ; ii ; anxiolytics anti-anxiety ; 1 ; benzodiazepines diazepam valium ; , chlordiazepoxide librium ; , lorazepam ativan ; , chlonazepam klonopin ; , clorazepate tranxene ; g ; drugs that treat mood disorders i ; tricyclic antidepressants tca ; 1 ; imipramine tofranil ; , amitriptyline elavil ; , mirtazapine remeron ; , nefazodone serzone ; , nortriptyline aventyl ; 2 ; idolamine - bupropion wellbutrin ; ii ; selective serotonin reuptake inhibitors ssris ; fluoxetine prozac ; , sertraline zoloft ; , paroxetine paxil ; , citalopram celexa ; , fluvoxamine luvox ; , venlafaxine effexor ; iii ; monoamine oxidase mao ; inhibitors phenelzine sulfate nardil ; , tranylcypromine parnate ; iv ; mood stabilizing drugs lithium carbonate eskalith ; , lithium citrate syrup h ; anti-psychotics i ; phenothiazines 1 ; chlorpromazine thorazine ; prototype, fluphenazine prolixin ; , trifluoperazine stelazine ; ii ; non-phenothiazines 1 ; clozapine clozaril ; , haloperidol haldol ; , molindone moban ; , olanzapine zyprexa ; , risperidone risperdal ; , thiothixene navane ; , loxapine loxitane ; i ; antiepileptic aed ; i ; barbiturates tonic-clonic ; phenobarbital, primidone mysoline ; , amobarbital amytal ; , mephobarbital mebaral ; ii ; hydantoins phenytoin dilantin ; , fosphenytoin cerebyx ; , mephenytoin mesatoin ; iii ; benzodiazepines absence ; - chlonazepam klonopin ; , diazepam valium ; , lorazepam ativan ; , clorazepate tranxene ; iv ; succinimides absence ; ethosuximide zarontin ; , methsuximide celontin ; , phensuximide milontin ; v ; oxazolidinediones absence ; paramethadione paradione ; , trimethadione tridione ; vi ; valproates tonic-clonic, partial, myoclonic, psychomotor ; valproic acid depakene ; , divalproex sodium depakote ; vii ; iminostilbenes carbamazepine tegretol ; , felbamate felbatol ; , gabapentin neurontin ; , lamotrigine lamictil ; , topiramate topamax ; j ; drugs that treat common neurological disorders i ; parkinsons 1 ; dopaminergic drugs levodopa larodopa ; , carbidopa-levodopa sinemet ; 2 ; anticholinergics - trihexyphenidyl artane ; , benztropine cogentin ; 3 ; other - amantadine symmetrel ; , pergolide permax ; , pramipexole mirapex ; , ropinirole requip ; , bromocriptine parlodel ; , selegiline eldepryl ; , entacapone comtan ; ii ; myasthenia gravis 1 ; neostigmine bromide prostigmin ; , edrophoniuim tensilon ; , pyridostigmine bromide mestinon ; , atropine sulfate and nexium. Extremely high mortality rate, based on local infectious complications, particularly in necrotising areas. Limited penetration of antimicrobial drugs in these areas is considered to be a major cause. KU-ZYME CAPSULE KUTRASE CAPSULE K-LYTE CL 50 MEQ CITRUS TAB K-LYTE TABLET EFF K-LYTE TABLET EFF K-LYTE TABLET EFF K-LYTE CL 25 MEQ TABLET EFF K-LYTE CL 25 MEQ TABLET EFF K-LYTE CL 25 MEQ TABLET EFF K-LYTE CL 25 MEQ TABLET EFF KLOTRIX 10 MEQ TABLET SA ANZEMET 20 mg ml VIAL ANZEMET 20 mg ml VIAL ANZEMET 12.5 mg CARPUJECT ANZEMET 20 mg ml VIAL COLYTE SOLUTION LEVATOL 20 mg TABLET LEVSIN 0.125 mg 5 ml ELIXIR LEVSIN 0.125 mg ml DROPS PROCTOCREAM-HC 2.5% CREAM PROCTOFOAM DESYREL 300 mg TABLET REGLAN 10 mg TABLET REGLAN 10 mg TABLET REGLAN 5 mg TABLET BUSPAR 5 mg TABLET BUSPAR 5 mg TABLET BUSPAR 10 mg TABLET BUSPAR 10 mg TABLET BUSPAR 15 mg TABLET BUSPAR 15 mg TABLET BUSPAR 30 mg TABLET COLYTE WITH FLAVOR PACKETS ROBAXIN 500 mg TABLET ROBAXIN-750 TABLET ROBAXIN-750 TABLET MONOPRIL 40 mg TABLET PRIFTIN 150 mg TABLET ARAVA 10 mg TABLET ARAVA 20 mg TABLET LANTUS 100 UNITS ml VIAL LANTUS 100 UNITS ml CARTRIDGE KETEK 300 mg TABLET KETEK PAK 400 mg TABLET and pepcid. Were taken to assess lipid levels and safety parameters creatinine kinase and liver enzymes ; . Lipid levels were measured by standard laboratory methods. Plasma highsensitivity C-reactive protein hsCRP ; levels were measured using the BNII nephelometer Dade Behring, Germany ; . Repeat MRI was scheduled at 12 months of treatment, because 6 months of treatment were required to observe plaque regression in the thoracic aorta 5 ; . Throughout the study period, all patients were asked to maintain their dietary habits. If patients had been receiving antihypertensive drugs, they continued these drugs. MRI of aortic wall. MRI was performed on the Signa 1.5-T Cvi scanner GE Medical Systems ; using a commercially available phased-array body coil. The transverse proton density-weighted PDW ; and T2-weighted T2W ; images of the thoracic descending and abdominal aortas were obtained using an electrocardiographically gated, breath-hold, double-inversion-recovery, fast-spin-echo se. Blumenfeld, H., Eisenfeld, L: Does a mother singing to her own newborn baby affect feeding in the NICU? Clinical Pediatrics in press ; Klein, A.M., Schoem, S.S., Altman, A., Eisenfeld, L.: Inflammatory Myofibroblastic tumor in the neonate: a case report. Otolaryngology-Head and Neck Surgery. 128: 145-147, 2003. Pichardo, R., Adam, J., Rosow, E., Eisenfeld, L.: Vibrotactile Stimulation System to Treat Apnea of Prematurity. Biomedical Intrumentation and Technology . 37: 3440, 2003. Eisenfeld, L., Hanrahan, P., Keibel, A. : Do Newborn Intensive Care Staff Know the Gender and First Names of their Patients ? Connecticut Medicine 66: 535-537, 2002 Brunquell, P., Glennon, C., DiMario, F., Lerer, T., Eisenfeld, L. : Prediction of Outcome for Children with Neonatal Seizures. J. Pediatr. 140: 707-712, 2002. Corrow, C., Lapuk, S., Mazzarella, K., Sable, A.Leopold, H., Eisenfeld, L.: Hypoplastic Left Heart Syndrome: Factors Influencing Therapeutic Choice. Connecticut Medicine 65: 195-203, 2001. Oh, J., Rosow, E., Bronzino, J., Enderle, J. Eisenfeld, L.: The Design and Development of a Biosensor to Measure the Concentration of Meconium in Amniotic Fluid. Biomedical Instrumentation and Technology 35: 46-56, 2001 and prilosec. PONV in various surgical populations in a clinical audit setting. The study included 671 consecutive surgical inpatients, aged 15 years or older, undergoing various procedures. The study focused on postoperative nausea visual analog scale scores every 4 hours and vomiting episodes within 72 hours. Both vomiting and retching were considered as emetic events. Surgery-related variables that were considered to have a possible effect on the proportion of patients experiencing PONV were examined. The bivariate Dale model for binary correlated outcomes was used to identify the potential risk factors of PONV. Postoperative incidence rates of nausea and vomiting were estimated from the data. Statistical calculations were conducted using all data available. Results were considered to be significant at the 5% critical level p 0.05 ; . Among the 671 patients in the study, 126 19% ; reported one or more episodes of nausea, and 66 patients 10% ; suffered one or more emetic episodes during the study period. There was a highly significant association between the two outcomes. Some risk factors were predictive of both nausea and vomiting age, gender, obesity, and previous history of PONV ; . History of migraine was almost significantly related to nausea p 0.052 ; but not to vomiting p 0.63 ; . Duration of surgery was unrelated to outcomes. However, the type of surgery was significantly associated with nausea but not with vomiting, except for urological procedures p 0.037 ; . Patients undergoing gynecological p 0.0082 ; , urological p 0.022 ; , and abdominal p 0.028 ; surgery had an increased risk of developing nausea and vomiting. Factors contributing to incidence of PONV Age. Papdimitriou and Livanios 2001 ; evaluated the occurrence of PONV in female surgical patients, aged 20 to 43 years of age. One hundred and twenty female patients scheduled for minor gynecological laparoscopy were randomly allocated to receive pretreatment with tropisetron 5mg n 57 ; or granisetron hydrochloride Kytril ; 1 mg in combination with metoclopramide Rreglan ; 5mg n 63 ; . The authors found that fewer patients in the combined treatment group experienced PONV 14% vs. 37%, p 0.008 ; or needed rescue antiemetic treatment 3% vs. 16%, p 0.038 ; . The combination of the antiemetics used were found to be superior, which can be explained by the fact that the two drugs have different mechanisms of action, thus preventing emesis by blocking different pathways. Was significantly prevented in aortic rings from losartantreated rats after banding compared with vehicle-treated banding animals Fig. 5 ; . Endothelium-Dependent Decrease in the Contractile Response to Ang II in Ring Preparations of Pressure-Overloaded Thoracic Aorta in Vitro. The contractile response to Ang II was markedly augmented by removal of the endothelium in either control Fig. 6A ; or pressureloaded rings Fig. 6B ; . When the concentration-response curves were compared between control and pressure-loaded rings after removal of endothelium, decreased response to Ang II in pressure-loaded rings was not observed, and rather the response was augmented significantly in the pressureloaded rings at lower concentrations of Ang II between 1 10 and 1 10 9 Fig. 6C ; . PD123319 did not influence the response to Ang II in the endothelium-denuded rings of either control or pressure-loaded rings data not shown ; . To determine the involvement of endothelium-derived NO in the decreased response to Ang II in pressure-loaded rings, the ring preparations with intact endothelium were treated with a NO synthase inhibitor L-NAME 1 10 4 M ; for 30 and tagamet.
American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004; 113: 14511465. Marcy M, principal investigator. Management of Acute Otitis Media. Evidence Report Technology Assessment Number 1. AHRQ Publication No. 01-E010. Rockville, Md: Agency for Healthcare Research and Quality, US Department of Health and Human Services, 2001. A full text copy of the guideline can be viewed at: : pediatrics.aappublications cgi content full 113 5 1451. A full text copy of the evidence report upon which the guideline is primarily based can be viewed at : hstat.nlm.nih.gov hq Hquest screen DirectAccess db 3639. The February 2003 issue of Critical Care Nurse ran an excellent article on "Managing Nausea and Vomiting". In this article Kytril is mentioned as being in the trial stages for postop use. Lowell General Hospital has been selected to further study this drug and clinical trials have allowed it to be marketed for post-op use at this time. The Lowell General hospital study involves the use of Reglaan 10 mg Pre-op and Kytril 0.1 mg at least 30 minutes prior to extubation. For each patient who receives this, a record is kept of any rescue drugs used if any episodes of nausea and or vomiting occur. Figure 1. R-etodolac induces growth inhibition in MM cell lines. A ; MM.1S ; , U266 f ; , RPMI8226 OE ; , INA-6 F ; , and OPM1 ; MM cells; B ; Dex-sensitive MM.1S ; and DEX-resistant MM.1R f ; MM cells; C ; RPMI8226 ; and doxorubicin-resistant RPMI-Dox40 OE ; MM cells; D ; DHL4 ; and MM.1S OE ; cells; as well as E ; normal peripheral mononuclear cells from 3 healthy volunteers, no. 1 ; , no. 2 f ; , and no. 3 OE ; were cultured for 48 hours in the presence of R-etodolac 0-2.5 mM ; . Cell growth was assessed by MTT assays, and data represent mean SD ; of quadruplicate cultures and protonix. In the fall of 2005, M4 students Carol Kitay and Carol Liebl were the recipients of a one-time Student Government Association scholarship, which was awarded to two M4 students who were setting up international clinical rotations. Kitay and Liebl, who each received , 000 to help with their recently concluded rotations in South Africa, were involved in a collaborative program between the University of Pretoria School of Medicine in South Africa and Stanford University School of Medicine in California. Following is a summary of their experience! In recent years he travelled widely. He went to Belfast Northern Ireland ; , the United States, Guyana, Canada, and China, while renewing friendships with colleagues, friends, and relatives. Alan was diagnosed with prostate cancer 7 years ago, but remained active until February 2007--always planning some new adventure. He underwent radiotherapy, and other oncology treatment, and, latterly, supportive palliative care from his family and the Mary Potter Hospice in Wellington. He is survived by his children Andrew Caselberg, Jane Ball, and Belinda Henshaw all of Wellington ; plus three grandchildren and bentyl. Low ; and nasal antral window were surgically performed in September 1983. The surgical contents were cultured in the mycology laboratory, where S. commune was identified in pure culture. This case was first presented at an annual regional meeting of the Am. Soc. Microbiol. at Wagner College, Staten Island, N.Y., in February 1985. It was generously shared by personal communication from E. Alture-Werber. ; Case 2. The second patient, a 75-year-old, obese female, was admitted in December 1984, suffering from pain of the right side of the head and face due to chronic maxillary sinusitis. Also present were hypertension, managed without drugs; a hiatus hernia and diverticulitis, treated with metoclopramide hydrochloride Reblan ; , cimetidine Tagamet ; , and antacids; upper epigastric pain; a possible lump in her left breast; and cataracts. Past history revealed that the patient was a type Il diabetic, managed on diet without medication, and had lost 40 lb in the previous year going from 210 to ca. 170 lb [ca. 95 to 77 kg] ; . A Caldwell-Luc procedure was performed on the right maxillary sinus. The patient was sedated intravenously, after which the sinus area was numbed with a solution containing 1% lidocaine with 0.001% epinephrine. A 2-cm window of the right maxillary sinus was created surgically. Within the sinus there was an accumulation of black necrotic debris and some purulent material filling the entire sinus. The specimen was sent to the department of pathology for bacterial and fungal culture and microdiagnosis. The maxillary antrum mucosa was markedly edematous and reddish; the entire mucosa was removed and sent for histopathology. Another window was cut into the nasoantral area, and iodoform gauze was packed in the maxillary sinus, brought out through the nasoantral window, and secured at the level of the nasal dorsum. The window of the maxillary sinus was closed, with the nasoantral window remaining open for drainage. The patient recovered without event, though she still complains of sinus pain nearly 1 year after surgery. Led by Dr. Alexandra Shields, investigators in the TTURC Research to Practice Core reported results of a survey of primary care physicians to assess their attitudes toward future genetic-based approaches for the treatment of nicotine dependence. As part of the survey, physicians were randomly assigned one of two scenarios describing a new test that would allow the physician to tailor smoking cessation treatment. Both scenarios were identical, with the exception of the test description. In one scenario, the test was described as a "genetic test" while in the other the test was described as a "serum protein" test. Physician respondents expressed a high likelihood of adopting genetic testing to tailor treatment overall; however, levels of anticipated adoption were higher for the serum protein test as compared to the genetic test. As reported in the February 2005 issue of the Journal of General Internal Medicine, barriers to adoption may include the limited genetics training of primary care physicians and limited time to provide appropriate informed consent and counseling based on test results. In related work published in American Psychologist, TTURC investigators argued that although self-identified race can be useful for tracking health disparities, it may be less appropriate as a proxy for human genetic heterogeneity in genetic studies of smoking and other behavioral traits. The authors warn that self-identified race variables have significant social risks. The authors suggest that a biologically relevant measure of geographical ancestry may be a more appropriate and accurate assessment. Written by Molly McGinn-Shapiro and Freddie Patterson and zantac. 1. Registration 2. Maritim hotel 3. Federal Institute for Drugs and Medical Devices Health ; 4. Federal Ministry for the Environment, Nature Conservation and Nuclear Safety BMU ; 5. Federal Ministry of Transport, Building and Urban Affairs BMVBS ; 6. Gustav-Stresemann-Institut GSI ; 7. Federal Ministry of Education and Research Research Press Centre 8. Campus of Diversity 12-30 May ; 9. Expo of Diversity 27-30 May ; 10.Local Floral Seed Project, City of Bonn. INTRODUCTION.1 SUMMARY OF ARGUMENT.3 ARGUMENT.7 I. THE SETTLEMENT IS UNFAIR 7 A. The Failure to Inform This Court and Objectors About the Size of the Class and the Likelihood that Class Members Will Be Able to Submit Documented Claims Requires Rejection of the Settlement 8 B. The Settlement Agreement Does Not Set Forth Clear Guidelines for Proving Out-of-Pocket Expenses.12 C. The 0, 000 Cap Is Unfair to the Class.15 D. A Better Means of Disbursing Funds to Class Members Is Available and Has Been Used Before by GlaxoSmithKline 17 II. THE SETTLEMENT AGREEMENT DOES NOT EXPLAIN WHAT HAPPENS TO ANY REMAINING FUNDS 19 A. Any Money Remaining in the Settlement Fund Should Be Awarded as a Cy Pres Distribution 19 B. Alternatively, If the Remaining Fund Is Not Awarded as a Cy Pres Distribution and Were to Revert to GlaxoSmithKline, the Settlement Will Be Unfair and Should Not Be Approved for that Reason.22 C. The Attorneys' Fee Award Is Unreasonable Without More Information About the Actual Value of the Settlement 23 1. Attorneys' fees should be awarded after the value of the settlement is assessed 26 2. Delaying the fee award creates good incentives and protects the class.28 III. THE RESTRICTION ON OPT-OUT CLASS MEMBERS' RIGHTS TO BRING CLASS ACTIONS IS UNENFORCEABLE 28 CONCLUSION .31 and carafate and Order reglan. History of ReglanReglan saleIf your military service is for 30 or fewer days, you and your family can continue coverage under the Plan at the same cost as before your short service. For example, if you are in the middle of a benefit period, your coverage is not affected. Likewise, if a selfpayment is owed to continue coverage, that selfpayment would still be owed. If your reduced hours from active duty of more than 30 days will result in your becoming ineligible under the Plan, you can continue your coverage under the Plan for your dependents by notifying the Company and the Fund Office of your service before you leave. If the Company stops making contributions, you and your family should be given notice. If you return to work for the Company within 90 days after your discharge, as described below, your health insurance will be reinstated to the same status as before you began your military service. Deadline for Applying for Work with the Company If the period of service in the uniformed services: Lasted less than 31 days Applicable deadline: By the beginning of the next regular scheduled work period on a day following completion of the uniformed service, and at least eight hours after the period needed for the participant to return home from the place of that uniformed service. 2. DIET: NPO Ice Clear Liquids Regular 3. NURSING ORDERS: Foley to gravity Discontinue Foley on Postop Day # at time ; I & O every shift X 48 hours Incentive Spirometry q 2h while awake Dressing care Drain care PRN Packing: Vaginal Remove on Day: by: Other: 4. IV FLUIDS: IV 1000 ml at ml hour X liters 8. IV FLUIDS: 5. MEDICATIONS: Prophylactic Antibiotics Prophylaxis less than 24 hrs post surgery, give reason if greater than 24 hrs ; : No prophylactic postoperative antibiotics recommended ; Cefazolin Ancef ; 1 gram IV every 8 hours X 3 doses Cefazolin Ancef ; 2 grams IV every 8 hours X 3 doses Ampicillin Sulbactam Unasyn ; 3 grams IV every 6 hours x 4 doses For patients with severe penicillin allergy or cephalosporin allergy only: Clindamycin Cleocin ; 600 mg IV q 8 hrs X 3 doses + Aztreonam Azactam ; 1 gram IV q 8 hrs x 3 doses Nausea: Pain: Metoclopramide Reglan ; 10 mg IV every 6 hours PRN nausea Ondansetron Zofran ; 4 mg IV every 6 hours PRN nausea Ibuprofen Motrin ; 600 mg PO every 6 hours PRN pain Ketorolac Toradol ; 30 mg IV every 6 hours around the clock x doses Ketorolac Toradol ; 30 mg IV every 6 hours PRN pain Patient Controlled Analgesia see separate order form and buy nexium. Reglan alcoholRelgan, regla, reglqn, reblan, reglah, reglxn, revlan, rdglan, reglann, reglna, rehlan, regglan, regllan, 5eglan, reflan, reglsn, relan, regkan, r4glan, reglab, regln, retlan, regaln, deglan. |